Hematopoiesis News 8.44 November 7, 2017 | |
| |
TOP STORYPlexin-B2 Mediates Physiologic and Pathologic Functions of Angiogenin Investigators showed that plexin-B2 (PLXNB2) is the functional receptor for angiogenin (ANG) in endothelial, cancer, neuronal, and normal hematopoietic and leukemic stem and progenitor cells. Mechanistically, PLXNB2 mediates intracellular RNA processing that contribute to cell growth, survival, and regenerative capabilities of ANG. [Cell] Abstract | Graphical Abstract | |
| |
PUBLICATIONS(Ranked by impact factor of the journal)Scientists observed a population of early-engrafting cells displaying HSC-like behavior, which persisted long-term in vivo in an autologous myeloablative transplant model in nonhuman primates. [Sci Transl Med] Abstract Somatic Mutations and Clonal Hematopoiesis in Congenital Neutropenia Investigators sequenced the exome of individual hematopoietic colonies derived from 13 patients with congenital neutropenia to measure total mutation burden and performed error-corrected sequencing on a panel of 46 genes on 80 patients with congenital neutropenia to assess for clonal hematopoiesis. [Blood] Abstract The interleukin (IL)-27 promotes expansion and differentiation of hematopoietic stem cells into myeloid progenitor cells. Many tumor-infiltrating myeloid cells exert immunosuppressive effects but researchers hypothesized that the myeloid cells induced by IL-27 would have antitumor activity. They corroborated this hypothesis as investigated in two distinct mouse transplantable tumor models. [Cancer Res] Abstract Endogenous Retinoid X Receptor Ligands in Mouse Hematopoietic Cells To identify natural ligands of retinoid X receptor α (RXRA) that are present in hematopoietic cells, the authors adapted an upstream activation sequence–green fluorescent protein reporter mouse to detect natural RXRA ligands in vivo. They observed reporter activity in diverse types of hematopoietic cells in vivo. [Sci Signal] Abstract Epidermal Growth Factor and G-CSF Signaling Are Synergistic for Hematopoietic Regeneration Scientists sought to identify epidermal growth factor (EGF) as a hematopoietic growth factor for chemotherapy-induced myelosuppression. Following 5-fluorouracil, EGF accelerated hematopoietic stem cell regeneration and prolonged survival compared to saline-treated mice. [Stem Cells] Abstract Researchers characterized for the first time deformability and size changes in CD34+ cells, and expelled nuclei, during their differentiation process into red blood cells at days 11, 14, 18 and 21, using real-time deformability cytometry and atomic force microscopy. [Sci Rep] Full Article Due to the importance of peripheral blood hematopoietic stem and progenitor cells (HPCs) in post-acute regeneration after acute myocardial infarction (MI), the authors investigated count and secondary replating capacity/self-renewal ability of HPCs in peripheral blood before and two weeks after MI. [Exp Physiol] Abstract CLINICAL RESEARCHIn this Phase I study, investigators tested increasing doses of TMI in addition to standard intravenous melphalan at 200 mg/m2 in the conditioning regimen prior to autologous stem cell transplant for multiple myeloma. [Leuk Lymphoma] Abstract | |
| |
REVIEWSThe Unique Structural and Functional Features of CXCL12 Scientists summarize the interactions of CXCL12 with the cellular environment and discusses the different levels of CXCL12 activity regulation. [Cell Mol Immunol] Abstract The authors discuss the therapeutic approaches targeting cis-regulatory regions to reactivate fetal hemoglobin for the treatment of β-hemoglobinopathies. Epigenetic studies allowed the definition of cis-regulatory sequences used by human hematopoietic cells. [Stem Cells Transl Med] Full Article Visit our reviews page to see a complete list of reviews in the hematopoiesis research field. | |
| |
SCIENCE NEWSClinical Trial Finds Blood-Plasma Infusions for Alzheimer’s Safe, Promising Investigators have reported success in an early-phase clinical trial examining the safety, tolerability and feasibility of administering infusions of blood plasma from young donors to participants with mild to moderate Alzheimer’s disease. [Press release from Stanford Medicine discussing research presented at the 10th Annual Clinical Trial on Alzheimer’s Disease Conference, Boston] Press Release | Editorial Genentech to Present New Data Across a Range of Blood Diseases Genentech announced that new data on its approved and investigational medicines for blood diseases will be presented. Ten Genentech medicines will be featured in over 75 abstracts, including 26 oral presentations, across eight blood diseases. [Press release from Genentech, Inc. discussing research to be presented at the 59th American Society of Hematology (ASH) Annual Meeting, Atlanta] Press Release BioLineRx Ltd. disclosed preclinical data of BL-8040 demonstrating that human CD34+ cells purified from BL-8040-mobilized grafts contain high numbers of a specific type of HSCs associated with long-term engraftment, compared to cells mobilized by granulocyte colony stimulating factor. [Press release from BioLineRx Ltd. discussing research to be presented at the 59th American Society of Hematology (ASH) Annual Meeting, Atlanta] Press Release | |
| |
INDUSTRY NEWSAltemiaâ„¢ Achieves Successful Clinical Results in Pediatric Patients with Sickle Cell Disease (SCD) Sancilio Pharmaceuticals Company, Inc. announced positive top line results from a clinical study evaluating the efficacy and safety of Altemia™, an oral soft gelatin dosage form, in pediatric sickle cell patients aged 5-17 years. [Sancilio Pharmaceuticals Company, Inc.] Press Release AstraZeneca and its hematology research and development centre of excellence, Acerta Pharma, announced that the FDA has granted accelerated approval to Calquence. [AstraZeneca] Press Release Verastem, Inc. announced that a meeting was held with the FDA regarding the regulatory path for duvelisib, the company’s first-in-class, oral, monotherapy, dual inhibitor of phosphoinositide 3-kinase (PI3K)-delta and PI3K-gamma, which is being developed for the treatment of patients with lymphoid malignancies. [Verastem, Inc.] Press Release Jazz Pharmaceuticals plc announced the submission of a Marketing Authorization Application to the European Medicines Agency’s Committee for Medicinal Products for Human Use for Vyxeosâ„¢ powder for concentrate for infusion to treat adults with high-risk acute myeloid leukemia (AML) defined as therapy-related AML or AML with myelodysplasia-related changes. [Jazz Pharmaceuticals plc] Press Release | |
| |
POLICY NEWSIndian Scientists Urged to Speak Out about Pseudoscience A leading Indian science-advocacy group is urging the country’s researchers to speak out against pseudoscience, which it fears has gained a foothold in the past few years, partly through support from some agencies of the Indian government. [Nature News] Editorial Court Demands that Search Engines and Internet Service Providers Block Sci-Hub The American Chemical Society (ACS) has won a lawsuit against Sci-Hub, a website providing illicit free access to millions of paywalled scientific papers. ACS had alleged copyright infringement, trademark counterfeiting and trademark infringement; a district court in Virginia ruled that Sci-Hub should pay the ACS $4.8 million in damages after Sci-Hub representatives failed to attend court. [ScienceInsider] Editorial
| |
EVENTSNEW International Society for Experimental Hematology (ISEH) 47th Annual Scientific Meeting Visit our events page to see a complete list of events in the community.
| |
JOB OPPORTUNITIESPhD Studentships – Cancer Research (University of Cambridge) Staff Scientist – Normal and Malignant Hematopoiesis (University of Copenhagen) Faculty Positions – Hematological Malignancies (University of Alabama at Birmingham) Postdoctoral Fellow – Hematology (University of Tennessee Health Science Center) Postdoctoral Fellowship – Development & Epigenetics (Centre National de la Recherche Scientifique) Postdoctoral Fellow – Hematopoietic Stem Cells (Memorial Sloan Kettering Cancer Center) Postdoctoral Positions – Stem Cell and Cancer Biology (Johns Hopkins University) Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
| |
Have we missed an important article or publication in Hematopoiesis News? Click here to submit! Comments or suggestions? Submit your feedback here. | |
|